Authors, year | Design | Study period | Setting | Population | Sample size | Mother age* | Comparison |
Pregnant women living with HIV | |||||||
Campbell, 201235 | RCT | 2005–2007 | Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, USA, Zimbabwe | Antiretroviral-naïve, non-pregnant adults, CD4 <350 cells/μL, continued ART if pregnant | 42 births | 34 | TDF/FTC/efavirenz versus AZT/3TC/efavirenz |
Fowler et al, 2016 (PROMISE)12 | RCT | 2012–2014 | India, Malawi, South Africa, Tanzania, Uganda, Zambia, Zimbabwe | HIV-positive women, ≥14 weeks’ gestation, CD4 ≥350 cells/mm3, 3490 | 694 | Median 26 (IQR 22–30) | TDF/FTC/LPV/r versus AZT/3TC/LPV/r |
Gibb, 201239 | Obs | 2003–2009 | Uganda, Zimbabwe | Infants born to HIV-positive mothers on combination ART | 173 | NR | TDF/AZT/3TC versus ABC/AZT/3TC or NVP/AZT/3TC |
Rough et al, 2017 (abstract)40 | Obs | 2002–2016 | USA | HIV-positive women with birth outcome information in a database | 1082 | NR | TDF/FTC/LPV/r versus AZT/3TC/LPV/r |
Wang, 201634 | RCT | 2012–2015 | China | HIV-positive women, antiretroviral-naïve, 14–28 weeks’ gestation, hepatitis B coinfection | 31 | Mean 28.5 (range 19–39) | TDF/3TC/LPV/r versus AZT/3TC/LPV/r |
Zash et al, 2017 (abstract)41 | Obs | 2014–2016 | Botswana | Births >24 weeks’ gestational age to HIV-positive women in maternity wards | 2584 | 34 (IQR 30–38) | TDF/FTC/NVP versus AZT/3TC/NVP and TDF/FTC/LPV/r versus AZT/3TC/LPV/r |
At risk but HIV-negative women receiving tenofovir/FTC for PrEP and become pregnant | |||||||
Mugo et al, 201415 | RCT | 2008–2013 | Kenya, Uganda | HIV serodiscordant heterosexual couples | 1785 | 33 (28–38) | TDF versus TDF/FTC versus placebo (discontinued when pregnancy detected) |
Van Damme et al, 2012*37 | RCT | 2009–2011 | Kenya, South Africa, Tanzania | Women at risk of for HIV acquisition | 2120 | Mean 24.2 | TDF/FTC versus placebo (discontinued when pregnancy detected) |
Bunge et al, 2015 (abstract)*36 | RCT | 2009–2011 | South Africa, Uganda, Zimbabwe | HIV-negative women using contraceptives | 428 | Median 23 (IQR 21–27) | TDF versus TDF/FTC versus placebo (discontinued when pregnancy confirmed) |
Women living with hepatitis B but not HIV | |||||||
Pan et al, 201638 | RCT | 2012–2013 | China | Women with active hepatitis B virus infection | 197 | Mean 27.1 | TDF versus placebo From 32 weeks |
*Excluded post hoc because of very low medication adherence.
3TC, lamivudine; ABC, abacavir; AZT, zidovudine, FTC, emtricitabine; LPV/r, lopinavir boosted with ritonavir; NR, not reprted; NVP, nevirapine; Obs, observational study; PrEP, pre-exposure prophylaxis; PROMISE, Promoting Maternal and Infant Survival Everywhere; RCT, randomised controlled trial; TDF, tenofovir.